Eurofins Scientific SE · EURONEXT:ERF

Eurofins Scientific — Investor Presentation (March 2023)

62 slides from Eurofins Scientific's investor presentation, March 2023

  1. Slide 1: Eurofins Corporate Presentation

    CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2021. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its af

  2. Slide 2: Disclaimer

    Disclaimer This presentation does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for or purchase securities in Eurofins Scientific S.E. and neither this document nor anything contained or referred to in it shall form the basis of, or be relied on

  3. Slide 3: Executive Summary

    Executive Summary CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2021]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 3

  4. Slide 4: Eurofins: The World Leader in Testing for Life

    Eurofins: The World Leader in Testing for Life Key Figures 35 years of value creation • Long-term track record of turning investments into growth, productivity, margin expansion and Return on Capital Employed ~900 laboratories 450,000,000+ • Competitive advantages based on tests performed each year

  5. Slide 5: What we do

    What we do ACTIVE WHEREVER TESTING CAN IN VITRO FOOD AND FEED TESTING DIAGNOSTICS AGRO TESTING PROTECT LIFE COSMETICS TESTING MATERIALS AND ENVIRONMENT ENGINEERING SCIENCES FORENSIC TESTING SERVICES AGROSCIENCE SERVICES BIOPHARMA SERVICES ASSURANCE GENOMIC SERVICES CONSUMER CLINICAL DIAGNOSTICS PROD

  6. Slide 6: Drivers for long-term market growth above GDP

    Drivers for long-term market growth above GDP Secular Underlying General Market Drivers Laboratory Market Drivers Fundamentals Demand for safe pharmaceuticals, Increasing wealth Consumer quality food and clean environment and quality of life expectations for protection Consolidation of the fragmente

  7. Slide 7: Strategy aims at building long-lasting competitive advantage

    Eurofins’ strategy aims at building long-lasting competitive advantage in very attractive markets Leading technology Quality of customer service • Competence Centres & R&D activities • Extensive expertise in local regulations for all major markets, and one-stop contact for compliance in multiple cou

  8. Slide 8: Building leadership positions in an industry with network effects

    Building leadership positions in an industry with significant network effects and competitive advantage for the market leader • High level of investment and innovation required to build and efficiently run a network of High barriers modern laboratories (buildings, equipment, IT infrastructure and so

  9. Slide 9: One-of-a-kind 'hub and spoke' laboratory network

    One-of-a-kind ‘hub and spoke’ laboratory network infrastructure is our platform for market leadership Spoke Eurofins’ network of laboratories Hub Local laboratories address immediate local Competence centres concentrate more specialised testing needs testing demands • Fast turnaround time for time-c

  10. Slide 10: Food & Feed hub and spoke network in North America

    Eurofins Food & Feed has built and operates the best-in- class hub and spoke network in North America HUB LABS Des Moines, IA Madison, WI Madison, WI New Orleans, LA Toronto, ON Toronto, ON Los Angeles, CA Minneapolis, MN Madison, WI SPOKE LABS Atlanta, GA Lancaster, PA Philadelphia, PA Battle Creek

  11. Slide 11: Building the Platform – Eurofins 2012 - Eurofins 2022

    Building the Platform – Eurofins 2012 - Eurofins 2022 2012 2015 2019 2020 2021 2022 2012-2022 ∆ Revenues (€ m) 1,044 1,950 4,563 5,439 6,718 6,712 20% CAGR Employees 10,890 18,382 43,320 50,000 58,000 61,000 19% CAGR (total headcount) Number of 170 225 >800 >800 900 900 +730 laboratories Number of c

  12. Slide 12: Eurofins is the leader in most of its markets

    Eurofins is the leader in most of its markets and continues to build global & local leadership positions* in markets where scale matters CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2020]. All rights reserved. Any use of this material without the specific permission of an auth

  13. Slide 13: Investments in start-ups are integral to long-term growth

    Investments in start-ups are integral to long-term growth and value creation Long track record Strategic rationale Contributions by start-ups in FY 2022 Number of start-ups created Complements M&A strategy: • When acquisitions are too expensive or Organic growth contribution Programme Total Per year

  14. Slide 14: Track record of integrating acquired businesses

    Eurofins has a good track record of successfully integrating acquired businesses Good pipeline of M&A opportunities 70 600 496 Number of acquisitions per year (average) 60 500 Cumulative number of acquisitions 437 50 399 373 400 347 40 295 300 30 235 59 60 52 200 20 127 38 26 26 100 10 18 10 0 0 199

  15. Slide 15: Operating Segments

    Operating Segments CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2021]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 15

  16. Slide 16: Leading global and local market positions in high-growth markets

    Leading global and local market positions in attractive high-growth markets* Testing for Food & Feed Testing Environment Testing Clinical Diagnostics Pharma/Biotech/Agrosciences Eurofins N°1 to N°3 N°1 N°1 Start-Up position* worldwide worldwide worldwide Started 2014 Started 2000-2005 Started 1987 S

  17. Slide 17: Global leadership positions in high potential niche markets

    Eurofins has also established global leadership positions in high potential niche markets Agroscience CRO** Advanced Materials Genomic Services Discovery Pharmacology Cosmetics Testing Services Sciences N°3 N°1 N°1 N°1 to N°2 N°1 Worldwide Eurofins position* worldwide worldwide worldwide worldwide N

  18. Slide 18: Present in several high growth Life Sciences markets

    Eurofins is also present in several high growth Life Sciences markets Oligonucleotides Production and In Vitro Diagnostics (IVD) Solutions Next Generation Sequencing (NGS) #3* worldwide Eurofins Start-up #3* in Europe position Start 2016 Start 2000 Gold Standard Diagnostics, previously known as Euro

  19. Slide 19: Food & Feed Testing

    Food & Feed Testing CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2020]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 19

  20. Slide 20: Best-in-class Food & Feed Testing network in Europe

    Eurofins operates the best-in-class Food & Feed Testing network in Europe Eurofins Food and Feed Testing European Network Market leader in significant markets • Nordics • Spain • Germany • Benelux • France • UK & Ireland 150 laboratories throughout Europe, including 5 hubs offering specialised testi

  21. Slide 21: Addressable food & feed testing market growth drivers

    Eurofins’ ~€4bn1 addressable global food & feed testing market enjoys robust growth drivers Globalisation: raw Consumers’ Outsourcing of Food scares and materials sourced increasing awareness industry’s internal or crises, widely covered from countries with and demand for safe state- owned in the me

  22. Slide 22: Food & Feed Testing market position and competitors

    Our leading Food & Feed Testing market position is underpinned by the trust of our customers Food & beverage Agriculture Retailers Restaurants & Caterers producers Customers1 & Contracts Global players International conglomerates Supermarket chains Major operators Caterers + regional & local markets

  23. Slide 23: Environment Testing

    Environment Testing CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2021]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 23

  24. Slide 24: Best-in-class Environment Testing network in Europe

    Eurofins operates the best-in-class Environment Testing network in Europe Eurofins Environment Testing European Network Market leader in significant markets • Nordics • Spain • Germany • Belgium • France • The Netherlands • Austria • Ireland 178 sites throughout Europe, including 9 hubs offering spe

  25. Slide 25: Eurofins Environment Testing U.S.

    Eurofins Environment Testing U.S. 60 Laboratory Locations ~3,000 Staff (2021) 4 million Samples (2021 actual) 550+ Accreditations & Certifications Environmental Testing Built Environment Testing Laboratory Locations Service Centre Locations Laboratory Locations CONFIDENTIAL AND PROPRIETARY - © Eurof

  26. Slide 26: Addressable environment testing market growth drivers

    Eurofins’ ~€5bn1 addressable global environment testing market enjoys robust growth drivers Progress in epidemiology & Rise in contamination & Increasing demand by citizens medicine has identified more pollution issues for a clean environment compounds as toxic Increasingly long list of products ide

  27. Slide 27: Environment Testing market position and competitors

    Our leading Environment Testing market position is underpinned by the trust of our customers Engineering, Consulting, Industry, Manufacturing & Soil & Hazardous Waste Governments, Universities Construction firms firms & Non-Profits Customers1 & Contracts Global players Global players Typical service

  28. Slide 28: Momentum behind expansion of PFAS testing

    Lots of momentum behind expansion of PFAS testing Regulatory agencies looking Ongoing studies & innovations by Our PFAS capabilities in Europe at PFAS Eurofins regarding PFAS Largest European PFAS in blood project biomonitoring PFAS in Antwerp, Belgium Large high-throughput hubs in Sweden & the Neth

  29. Slide 29: BioPharma Services

    BioPharma Services CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2021]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 29

  30. Slide 30: BioPharma services span the complete product development cycle

    Eurofins BioPharma services span the complete product development cycle CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2021]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is str

  31. Slide 31: Leading Global BioPharma Services Network

    Leading Global BioPharma Services Network Leader in significant markets • Global leader in BioPharma Product Testing, Discovery Pharmacology Services and Agroscience CRO Services 122 laboratories 112 customer sites managed by Eurofins PSS1 Insourcing Solutions 300,000+ m2 laboratory capacity 10,000+

  32. Slide 32: BioPharma Services Evolution

    BioPharma Services Evolution Started Select milestones / acquisitions Market position today 2011: Global infrastructure established (US, Netherlands, 2001 Central Laboratory / bioanalytical Acquisitions: Singapore, China, India) Among top 5 global players 2005 Genomic Services Acquisitions: Among to

  33. Slide 33: BioPharma Clients & Peers

    BioPharma Clients & Peers Major Biopharma companies Innovative biotech Agroscience Supported the rapid Major operators development of COVID-19 therapeutics & vaccines Clients1 + regional & local players + numerous players from + regional & local players around the world Typical contractual ➢ Product

  34. Slide 34: R&D Spend Evolution

    R&D Spend Evolution Worldwide Total Pharmaceutical R&D Spend ($bn)1 Market drivers R&D spend continues to grow substantially, driven by 300 285 intensity & speed of innovation 272 278 265 247 256 • Increased focus on biologics vs. small molecules 250 238 238 = increasing amounts spent per drug 207 •

  35. Slide 35: Large Market Opportunities

    Large Market Opportunities Novel innovations1 Cell replacement Opportunities for Eurofins Chemicals Biologics Gene therapy Gene modified cell Description / Increasing complexity in Complexity2 testing and clinical trials Altering of genetic material Increased likelihood of outsourcing of testing Evi

  36. Slide 36: Cell & Gene Therapy Developments

    Cell & Gene Therapy Developments Revenues from cell & gene therapy1 Next stage of market development1 2 Eurofins already an active player serving Mid-term investment programme will allow cell & gene therapy customers Eurofins to capture growing future demand CONFIDENTIAL AND PROPRIETARY - © Eurofins

  37. Slide 37: Clinical Diagnostics

    Clinical Diagnostics CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2021]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 37

  38. Slide 38: Clinical diagnostics market growth drivers

    Eurofins’ clinical diagnostics market enjoys robust growth drivers Outsourcing of Efforts to optimise Aging & growing Medical and scientific hospital’s internal or healthcare system population innovations state- owned costs laboratories Need for earlier & more diagnosis Advances in genomics, genetic

  39. Slide 39: Portfolio of specialised clinical diagnostics laboratories

    Eurofins has built a valuable portfolio of specialised clinical diagnostics laboratories Genomics Infectious Diseases Organ transplants Oncology Women’s Health Robust portfolio of infectious Testing services supporting Advanced suite of molecular Custom DNA & RNA synthesis, Supporting women before,

  40. Slide 40: ESG

    ESG CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2021]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 40

  41. Slide 41: Further progress in all dimensions of ESG

    Further progress in all dimensions of ESG Environment Social Strong female representation in Achieved further reduction in carbon intensity leadership roles: • 47% female leaders at all leadership Carbon intensity by revenue (tCO2e/€m) (market-based) levels 98 • 25% female representation at the Grou

  42. Slide 42: Eurofins is an ESG enabler

    Eurofins is an ESG enabler Supporting a healthy environment Emphasising sustainable testing We value biodiversity Our testing services help improve health We have a strong commitment to the The Eurofins Foundation supports outcomes, ensure food safety and protect 3R strategy multiple biodiversity co

  43. Slide 43: Our long-term track record

    Our long-term track record CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2021]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 43

  44. Slide 44: Dedicated to long-term value creation

    Eurofins is dedicated to long-term value creation Our capital allocation priorities Rationale • Unlocks economies of scale Infrastructure programme building best-in-class hub • Custom built for purpose to improve productivity 1 and spoke laboratory network including ownership • Reduces risk of rent

  45. Slide 45: Increased net capex in 2022 to support strategic initiatives

    Increased net capex in 2022 to support strategic initiatives Strategic investment initiatives for (€m) 2018 2019 2020 2021 2022 accelerating growth Leasehold improvements (LHI) & others 95 55 71 117 146 Owned sites to complete hub and spoke network % of revenues 2.5% 1.2% 1.3% 1.7% 2.2% • Ownership

  46. Slide 46: Increasing site ownership creates long-term value

    Increasing site ownership creates significant long-term value Discretionary decision to increase proportion of owned sites Site ownership has high strategic value Surface area (m2) by site ownership 3x total Site ownership is key to expanding high-throughput 2018 surface area 2022 laboratory campuse

  47. Slide 47: Food Testing campus in U.S. demonstrates value of site ownership

    Food Testing campus in U.S. demonstrates value of strategic ownership of key strategic sites 2019 2022 Advantage: significant space savings Madison, Wisconsin Laboratory surface area (m2) Sites 2019 ➢ Footprint optimisation – consolidated -41% consolidating smaller into large 2022 sites into large c

  48. Slide 48: Expanding list of owned sites in high growth markets

    Expanding list of owned sites in high growth markets and regions (examples of sites) BioPharma, Specialty Clinical Diagnostics, Genomics Asia - Pacific Bangalore, India Milan, Italy Lenexa, Kansas, USA Dongguan, China Yokohama, Japan 21,400 m2 17,400 m2 10,200 m2 14,400 m2 4,000 m2 St. Charles, Miss

  49. Slide 49: Investments in start-ups and long-term value creation

    Investments in start-ups are integral to long-term growth and value creation Revenue development Profitability development Cash flow development Revenues EBITDA Operating cash flow and capex Establish Ramp Establish Ramp Establish Ramp Group ~ average margin Year 1 2 3 4 5 0 Operating cash flow Cape

  50. Slide 50: Fully digital with proprietary IT solutions

    Ongoing investments to be fully digital by deploying sector-leading proprietary IT solutions 30+ years of innovation with bespoke proprietary Laboratory Information Management Systems (LIMS) specific to each business line 1990s Today and beyond • 1991: Started development of proprietary eLIMS for fo

  51. Slide 51: Proprietary eLIMS-BPT + LabAccess offers more for clients

    Eurofins’ own eLIMS-BPT + LabAccess offers more for clients and costs less than externally available solutions External bioanalytical LIMS on market Eurofins’ proprietary eLIMS-BPT solution Standard feature set Standard feature set + Expanded, value-added feature set Testing Testing Billing & Sample

  52. Slide 52: Well positioned for big data analysis

    Our technological capabilities and scientific expertise make Eurofins well positioned for “big data” analysis Reference Examples: clinical testing for samples rare diseases and oncology Sa mp le Big data Generate full set of Match repository Generate full set of Sa data from the tested against refer

  53. Slide 53: Case study: AI improves productivity of Asbestos testing

    Case study: AI1 improves productivity of Asbestos testing Asbestos testing market Traditional asbestos Improved asbestos testing flow in France testing flow Pre-analysis / Pre-analysis / Preparation Preparation 10 million Growth samples driven by per year2 regulation Analysis Analysis Eurofins is th

  54. Slide 54: Among the best in Total Shareholder Return since 1997 IPO

    Eurofins has been among the best in the world in terms of Total Shareholder Return1 since its 1997 IPO Superior performance Best among peers Among the best in the world 140 €126.44 @ 21/09/21 120 100 80 60 €64.78 40 20 €0.1829 0 24/10/1997 24/10/1998 24/10/1999 24/10/2000 24/10/2001 24/10/2002 24/10

  55. Slide 55: Eurofins has consistently outperformed TIC peers

    Eurofins has consistently outperformed TIC peers Reported Revenues, €m 7,000 6,718 6,712 6,237 6,138 6,608 5,905 5,925 6,000 5,566 5,651 5,422 5,471 5,439 5,188 5,312 5,100 4,981 4,796 5,235 5,000 4,635 4,689 4,549 4,172 4,601 3,902 3,933 4,563 4,000 3,781 3,744 3,375 3,129 3,165 3,241 2,901 3,000 3

  56. Slide 56: Conclusion: our sustainable competitive advantage

    Conclusion: our sustainable competitive advantage Best in class technology and quality give best brand High-growth, non-cyclical markets driven by secular mega- protection trends N° 1 or 2 worldwide in most business lines Advancing globalisation but with very few global testing Operating in 61 count

  57. Slide 57: Appendix

    Appendix CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2021]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 57

  58. Slide 58: M&A Value Creation: Covance Food Solutions 1/2

    M&A Value Creation Case study: Covance Food Solutions (CFS) 1/2 Integration in US Food & Feed Testing Laboratory Network • Acquisition of CFS brought 9 facilities to US network • 7 new laboratories renovated or newly constructed to optimise hub & spoke network • 6 of the CFS facilities in the US wer

  59. Slide 59: M&A Value Creation: Covance Food Solutions 2/2

    M&A Value Creation Case study: Covance Food Solutions (CFS) 2/2 Key highlights Key drivers of value creation • CFS acquired in August 2018 from LabCorp • 12 facilities (9 US, 2 UK, 1 Singapore) • Acquisition rationale: • Significantly strengthened scale and scientific depth of US Food & Feed Testing

  60. Slide 60: M&A Value Creation: TestAmerica 1/2

    M&A Value Creation Case study: TestAmerica (TA) 1/2 Integration in US Environment Testing Laboratory Network • Acquisition of TA brought 24 laboratories to US network • 7 new laboratories renovated or newly constructed to optimise hub & spoke network • 10 of TA laboratories and 6 of Eurofins laborat

  61. Slide 61: M&A Value Creation: TestAmerica 2/2

    M&A Value Creation Case study: TestAmerica (TA) 2/2 Key highlights Key drivers of value creation • TestAmerica acquired in October 2018 from JSTI Group Environment testing and sampling still affected by COVID in 2020 and 2021 • 24 full service testing laboratories and 40 service centres throughout t

  62. Slide 62: Definitions / Alternative Performance Measures (APMs)

    Definitions / Alternative Performance Measures (APMs) APMs used in this presentation Adjusted results – reflect the ongoing performance of the mature and recurring activities excluding “separately disclosed items”. Separately disclosed items (SDI) – include: • one-off costs from integration and reor

Eurofins Scientific — Investor Presentation (March 2023) on 6ix